TELA Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $55.71M
- P/E (TTM)
- –
- Dividend yield
- –
About TELA Bio
Surgical & Medical Instruments & Apparatus, SIC 3841
The company is a commercial-stage medical technology firm that focuses on developing and commercializing soft-tissue reconstruction products. Its main offerings consist of the OviTex and OviTex PRS lines of reinforced tissue matrices, which integrate minimally processed ovine rumen biologic material with interwoven polymer fibers to support natural tissue remodeling and repair. These devices serve surgical procedures including ventral, inguinal, and hiatal hernia repairs, abdominal wall reconstruction, and plastic and reconstructive surgery. The company also distributes complementary surgical products such as hernia mesh fixation devices. It primarily serves surgeons, hospitals, and healthcare providers, reaching them directly or through national group purchasing organizations and integrated delivery networks.
The company markets its products primarily through a direct sales force in the United States, supplemented by sales representatives, independent contractors, and distributors in the United Kingdom and European Union. Exclusive product manufacturing is conducted by a partner facility situated in Auckland, New Zealand. The provided excerpt does not disclose the location of the company's corporate headquarters.
Summary of the business section of TELA Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TELA Bio, Inc.
- Headquarters
- Malvern, PA
- Address
- 1 Great Valley Parkway, Suite 24 19355
- Phone
- (484) 320-2930
- Employees
- 218, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Philadelphia, PA
Stock & identifiers
- Ticker
- TELA
- Exchange
- Nasdaq
- IPO date
- Nov 8, 2019
- Shares outstanding
- 45M, Aug 5, 2026
- Public float
- $76.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1561921
- CUSIP
- 872381108
- ISIN
- US8723811084
- EIN
- 45-5320061
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Heather C. Getz | Chief Executive Officer, Director | 532,500 |
| Antony Koblish | Chief Executive Officer, Director | 586,210 |
| Howard N. Langstein | Chief Medical Officer | 71,347 |
| Paul Talmo | Chief Technology Officer | 173,436 |
| Jeffrey Blizard | President | 205,125 |
| Gregory A. Firestone | Chief Business Officer | 139,307 |
| Megan Smeykal | Chief Accounting Officer | 66,873 |
| Roberto Cuca | COO and CFO | 257,377 |
| Joseph H. Capper | Director | 179,827 |
| William J. Plovanic | Director | 44,530 |
| Guido J. Neels | Director | 23,600 |
| Betty Jo Rocchio | Director | 23,600 |
| Guy P. Nohra | Director | 23,600 |
| Paul Thomas | Director | 23,600 |
| Kurt Azarbarzin | Director | 532,951 |
| Vincent J. Burgess | Director | 23,330 |
| Federica F. O'Brien | Director | 18,470 |
| Douglas G. Evans | Director | 18,470 |
| Lisa N. Colleran | Director | 18,470 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Anthony Koblish | $1.97M | $889.04K | $995.64K | $10 | – |
| FY2024 Anthony Koblish | $2.11M | $883.29K | $948.96K | $26 | – |
| FY2023 Anthony Koblish | $2.37M | $1.16M | $1.01M | $58 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 218 employees worldwide.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 18, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 20, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 8, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 7, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |